Indicated for: breast cancer
Route of administration: oral
Substance: anastrozole (aromatase inhibitor)
ATC: L02BG03 (Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Aromatase inhibitors)
Anastrozole is a medication used in the treatment of hormone-dependent breast cancer in postmenopausal women. It belongs to the class of aromatase inhibitors and works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens. By reducing estrogen levels, anastrozole slows the growth of tumors that depend on this hormone.
Anastrozole is taken orally, usually once daily, and treatment may last for several years depending on the stage of the disease and the patient's response.
Common side effects include hot flashes, joint pain, fatigue, nausea, and osteoporosis. In rare cases, severe adverse reactions such as bone fractures or liver function impairment may occur.
Patients taking anastrozole should undergo regular monitoring for bone density and liver function. Additionally, the medication is not indicated for premenopausal women or those who are pregnant. Anastrozole is an effective option for managing hormone-dependent breast cancer, contributing to improved patient outcomes.